
XTNT Stock Forecast & Price Target
XTNT Analyst Ratings
Bulls say
Xtant Medical Holdings is a medical technology company with a comprehensive portfolio of innovative orthobiologics and spinal implant systems. The company's consistent product growth and strong financials, including a projected 10% CAGR through FY28, provide a strong foundation for success in the future. Furthermore, recent strategic acquisitions and partnerships, such as the Dilon Technologies agreement and the sale of its Coflex, CoFix, and OUS businesses, showcase the management team's commitment to profitable growth and the potential for future upside. With shares trading at a discount to peers and the company's clear focus on expanding its global presence, we believe Xtant Medical Holdings presents a compelling investment opportunity with limited downside risk.
Bears say
Xtant Medical Holdings is facing significant challenges, starting with the ending of their OEM opportunities from licensing on SimpliMax's Q-code. Additionally, with competition, lower legacy performance, and a potential need for additional capital, combined with the softer-than-expected procedure environment, the company is at risk for decreased revenue and financial instability. This negative outlook is further supported by the fact that the company's key financial metrics, such as revenue and operating margin, have been declining over the past few years and are expected to continue on this downward trend in the near future.
This aggregate rating is based on analysts' research of Xtant Medical Holdings and is not a guaranteed prediction by Public.com or investment advice.
XTNT Analyst Forecast & Price Prediction
Start investing in XTNT
Order type
Buy in
Order amount
Est. shares
0 shares